Abstract: Genomic technologies including expression microarrays and genotyping platforms offer unprecedented opportunities to advance our understanding of the contribution of environmental, genetic, and epigenetic factors towards modification of disease progression. Towards this end, we propose to use an integrative genomics approach to identify differentially expressed genes and their biologically relevant genetic variation impacting clinical severity in cystic fibrosis (CF), an inherited multisystem disease characterized by progressive deterioration in lung function and pancreatic insufficiency attributed to dysfunction of a single gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). In 2001, Jansen and Nap proposed combining genome-wide expression data with population genetics to identify sequence variants that regulate gene expression and in turn impact clinical phenotypes. Our premise is that such an approach is relevant to understanding the pathogenic mechanisms responsible for CF and chronic inflammatory lung diseases in general. Our unique multicenter collaboration, incorporating CF patients enrolled in the Wisconsin Newborn Screening Program, will ensure needed longitudinal follow-up of young patients necessary to confirm current findings and define complex associations. The resulting data will define a molecular phenotype of genes involved in early infections of the CF lung by P. aeruginosa and the contribution of host response to clinical outcome. This project has several important implications for identification of functional genetic variation in novel molecular targets and development of novel clinical diagnostic and prognostic tools. Public Health Relevance: Cystic fibrosis (CF) lung disease is characterized by chronic infection by Pseudomonas aeruginosa and is the major cause of morbidity and mortality in CF patients. The resulting data will define a molecular phenotype of genes involved in early infections of the CF lung by P. aeruginosa and the contribution of host response to clinical outcome. This project has several important implications for identification of functional genetic variation in novel molecular targets and development of novel clinical diagnostic and prognostic tools.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
NIH Director’s New Innovator Awards (DP2)
Project #
1DP2OD007031-01
Application #
7980526
Study Section
Special Emphasis Panel (ZGM1-NDIA-O (01))
Program Officer
Basavappa, Ravi
Project Start
2010-09-30
Project End
2015-06-30
Budget Start
2010-09-30
Budget End
2015-06-30
Support Year
1
Fiscal Year
2010
Total Cost
$2,250,000
Indirect Cost
Name
Medical College of Wisconsin
Department
Pediatrics
Type
Schools of Medicine
DUNS #
937639060
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Ideozu, Justin E; Zhang, Xi; Pan, Amy et al. (2017) Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis. Int J Mol Sci 18:
Levy, H; Nugent, M; Schneck, K et al. (2016) Refining the continuum of CFTR-associated disorders in the era of newborn screening. Clin Genet 89:539-49
Machogu, Evans; Cao, Yumei; Miller, Tami et al. (2015) Comparison of WHO and CDC growth charts in predicting pulmonary outcomes in cystic fibrosis. J Pediatr Gastroenterol Nutr 60:378-83
Levy, Hara; Farrell, Philip M (2015) New challenges in the diagnosis and management of cystic fibrosis. J Pediatr 166:1337-41
Corvol, Harriet; Blackman, Scott M; Boëlle, Pierre-Yves et al. (2015) Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat Commun 6:8382
Parker-McGill, Katelyn; Nugent, Melodee; Bersie, Rachel et al. (2015) Changing incidence of cystic fibrosis in Wisconsin, USA. Pediatr Pulmonol 50:1065-1072
Miller, Melissa R; Soave, David; Li, Weili et al. (2015) Variants in Solute Carrier SLC26A9 Modify Prenatal Exocrine Pancreatic Damage in Cystic Fibrosis. J Pediatr 166:1152-1157.e6
Sanders, Don B; Li, Zhanhai; Laxova, Anita et al. (2014) Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc 11:63-72
Levy, H; Wang, X; Kaldunski, M et al. (2012) Transcriptional signatures as a disease-specific and predictive inflammatory biomarker for type 1 diabetes. Genes Immun 13:593-604
Sebro, R; Levy, H; Schneck, K et al. (2012) Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency. Clin Genet 82:546-51

Showing the most recent 10 out of 12 publications